A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.

Abstract

BACKGROUND/AIM:

Gemcitabine (GEM)-induced vascular pain often occurs in patients. A 5% glucose solution for the lyophilized formulation of GEM solvent is known to decrease the frequency of GEM-induced vascular pain compared with saline. In this study, we aimed to examine the availability of glucose for a liquid formulation GEM solvent for the prevention of GEM-induced vascular pain.

PATIENTS AND METHODS:

In total, 214 patients with bile tract or pancreatic cancer, who received GEM-containing regimens, were enrolled in this retrospective study. The patients were divided into a glucose group, which was administered the liquid formation GEM diluted with glucose, and a saline group. The frequency of GEM-induced vascular pain was compared between them.

RESULTS:

Glucose significantly decreased the frequency of GEM-induced vascular pain during the first GEM administration (36% vs. 55%, p=0.005).

CONCLUSION:

Switching the solution for liquid formulation GEM from saline to glucose significantly decreased the frequency of vascular pain.

• Authors: Kazuki Uchiyama, Yoshitaka Saito, Tatsuhiko Sakamoto, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
• Journal: Anticancer research (Anticancer Res) Vol. 42 Issue 1 Pg. 343-348 (Jan 2022) ISSN: 1791-7530 [Electronic] Greece
• PMID: 34969743 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Deoxycytidine
• Glucose
• Gemcitabine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Biliary Tract Neoplasms
• Blood Vessels (drug effects, pathology)
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
• Female
• Glucose (administration & dosage)
• Humans
• Male
• Middle Aged
• Pain (drug therapy, pathology)
• Pancreatic Neoplasms (drug therapy, pathology)
• Gemcitabine